Six-year follow-up of a personalised mRNA vaccine in pancreatic cancer: 7 of 8 immune responders alive (phase 1, 16 patients)

In a phase 1 trial of autogene cevumeran — a personalised mRNA vaccine given after resection of pancreatic cancer — 8 of 16 patients mounted a tumour-specific immune response. After 4-6 years of follow-up, 7 of those 8 were alive, compared with 2 of 8 non-responders (median survival 3.4 years). The data were presented at the 2026 AACR Annual Meeting. The study was small and non-randomised, so the gap between the groups cannot be read as evidence of efficacy — patients capable of mounting an immune response may differ from the rest in other ways as well; an ongoing global phase 2 trial is designed to settle the question.